Clinical Trials

16 enrolled

Melanoma

NCT04708418 2026-03-18

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Phase 2/3 Active not recruiting

Melanoma

NCT02339571 2026-03-17

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

600 enrolled

Melanoma

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05571839 2026-03-13

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

DermatologicGastrointestinalOther solid neoplasmThoracic

41 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Melanoma

NCT04478318 2026-03-10

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

DermatologicLymphoidThoracic

180 enrolled

Lung Neoplasms, Lymphoma, Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

20 enrolled

Melanoma

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT01644591 2026-03-05

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

49 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

DermatologicLymphoidSarcoma

15 enrolled

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Melanoma, Recurrence

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

26 enrolled

Melanoma, Skin Neoplasms

NCT05907304 2026-02-27

SEACRAFT-1

DermatologicGastrointestinalHead & NeckThoracic

86 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

78 enrolled

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Melanoma

NCT07428252 2026-02-25

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

150 enrolled

Melanoma

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

2 enrolled

Melanoma

NCT00338377 2026-02-23

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

1,230 enrolled

Melanoma, Meningeal Neoplasms

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

26 enrolled

Melanoma

NCT06870487 2026-02-19

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

DermatologicHead & NeckLymphoidOther hematologic neoplasmThoracic

6 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Hodgkin Disease, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT05068102 2026-02-18

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

DermatologicHead & NeckThoracic

14 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

DermatologicHead & NeckThoracic

15 enrolled

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT02816021 2026-02-17

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

24 enrolled

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Melanoma

NCT03699995 2026-02-13

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

100 enrolled

Melanoma, Nevus, Pigmented

NCT03767348 2026-02-13

IGNYTE

340 enrolled

DermatologicThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06014086 2026-02-11

Intratumoral PH-762 for Cutaneous Carcinoma

30 enrolled

Melanoma

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

151 enrolled

Melanoma, Skin Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

BreastCNSDermatologicGenitourinary

125 enrolled

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT04866680 2026-02-09

PERCIMEL

136 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

18 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled